2015
Biosimilar biologics: never identical but close enough
Abi‐Raad R, Smith BR. Biosimilar biologics: never identical but close enough. Transfusion 2015, 55: 229-231. PMID: 25683185, DOI: 10.1111/trf.12961.Peer-Reviewed Original Research
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashionUse of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, ViralAntineoplastic AgentsBlood Component TransfusionBlood DonorsDNA, ViralGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHumansImmunosuppression TherapyLymphocytesLymphoproliferative DisordersMalePolymerase Chain ReactionRituximabConceptsEpstein-Barr virus-associated lymphoproliferative disorderStem cell transplantationEBV DNA titersB cell populationsCell transplantationTherapeutic strategiesEpstein-Barr virus-associated lymphoproliferationHaplo-identical stem cell transplantationEffective alternative therapeutic strategyAllogeneic stem cell transplantationCourses of rituximabDonor-derived lymphocytesPost-transplant immunosuppressionMonoclonal B-cell populationCD20 monoclonal antibodyCell populationsAlternative therapeutic strategiesImmunosuppressive medicationsSevere GVHDHost diseaseLymphocyte infusionPost transplantFatal complicationCurative therapyLymphoproliferative disordersSelective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation
Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch J, Li L, Rollins SA, Smith BR. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. Journal Of Thoracic And Cardiovascular Surgery 1999, 118: 460-466. PMID: 10469960, DOI: 10.1016/s0022-5223(99)70183-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalBlood PlateletsComplement ActivationComplement C3aComplement C8Complement Membrane Attack ComplexEnzyme-Linked Immunosorbent AssayExtracorporeal CirculationFlow CytometryHumansLeukocyte CountLeukocyte ElastaseMacrophage-1 AntigenNeutrophil ActivationNeutrophilsP-SelectinPlatelet ActivationPlatelet CountReference ValuesConceptsNeutrophil activationExtracorporeal circuitExtracorporeal circulationLeukocyte activationMembrane attack complexPlatelet activationC5b-9C5b-9 generationAttack complexC5b-9 formationMembrane attack complex formationPlatelet CD62PControl circulationCardiopulmonary bypassLate complement componentsPlatelet countMonocyte countInhibits plateletSelective blockadeLoss of monocytesExtracorporeal modelSC5b-9Complement activationComplement componentsCellular activation
1995
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. Journal Of Clinical Investigation 1995, 96: 1564-1572. PMID: 7657827, PMCID: PMC185782, DOI: 10.1172/jci118195.Peer-Reviewed Original ResearchConceptsCardiopulmonary bypassExtracorporeal circulationSerum complement hemolytic activityComplement activationComplement componentsP-selectin-positive plateletsC5 complement componentNeutrophil CD11b upregulationSystemic inflammatory responseBlockade of C5aComplement hemolytic activityC5b-9 generationNeutrophil activationCD11b upregulationControl MAbInflammatory responseTherapeutic interventionsPlatelet activationCellular activationC5b-9BypassC5aC3a generationConjugate formationPlatelets
1991
Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E, Reichert T, Blythman H, Bouloux C, Rappeport J, Burakoff S, Weinstein H. Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies. Blood 1991, 78: 2139-2149. PMID: 1717080, DOI: 10.1182/blood.v78.8.2139.2139.Peer-Reviewed Original ResearchConceptsAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patientsDynamics of leukocyte-platelet adhesion in whole blood.
Rinder H, Bonan J, Rinder C, Ault K, Smith B. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991, 78: 1730-7. PMID: 1717069, DOI: 10.1182/blood.v78.7.1730.bloodjournal7871730.Peer-Reviewed Original ResearchActivated and unactivated platelet adhesion to monocytes and neutrophils.
Rinder H, Bonan J, Rinder C, Ault K, Smith B. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991, 78: 1760-9. PMID: 1717070, DOI: 10.1182/blood.v78.7.1760.bloodjournal7871760.Peer-Reviewed Original Research
1990
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Progress In Clinical And Biological Research 1990, 333: 207-15. PMID: 1689852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, MonoclonalAntigens, CDAntigens, DifferentiationBone MarrowBone Marrow CellsBone Marrow TransplantationCD5 AntigensChildChild, PreschoolCombined Modality TherapyCyclophosphamideCytarabineDrug EvaluationGraft vs Host DiseaseHumansImmunotoxinsLeukemiaMiddle AgedMyelodysplastic SyndromesRicinRisk FactorsT-LymphocytesWhole-Body Irradiation
1989
A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation.
Bierer B, Burakoff S, Smith B. A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood 1989, 73: 1359-66. PMID: 2467708, DOI: 10.1182/blood.v73.5.1359.bloodjournal7351359.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntigens, DifferentiationAntigens, Differentiation, T-LymphocyteBone Marrow TransplantationCalciumCD3 ComplexCD5 AntigensCytoplasmCytotoxicity, ImmunologicGraft vs Host DiseaseHumansImmunologic Deficiency SyndromesInterleukin-2Leukocyte CountMicePhenotypeReceptors, Antigen, T-CellT-Lymphocytes, CytotoxicConceptsBone marrow transplantationCD5 expressionMarrow transplantationT cellsAllogeneic bone marrow transplantationFrequency of CD3Major histocompatibility complex compatibilityT-cell depletionPercent of CD8Expression of CD5Presence of graftBMT patientsTotal CD3Host diseaseInterstitial pneumonitisPreparative regimenPeripheral bloodT lymphocytesB cellsCD3Lectin stimulationPatientsNormal populationTransplantationCD5Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2 concentrations
Guinan E, Smith B, Doukas J, Miller R, Pober J. Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2 concentrations. Cellular Immunology 1989, 118: 166-177. PMID: 2562928, DOI: 10.1016/0008-8749(89)90366-3.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsIL-2 concentrationsPolyclonal mitogen phytohemagglutininT cell responsesEndothelial cellsBlood monocytesUnfractionated peripheral blood mononuclear cellsCell responsesPrimary allogeneic responseSuboptimal PHA concentrationsExogenous IL-2Blood mononuclear cellsT cell populationsRecombinant IL-1Cultured human endothelial cellsDermal fibroblastsIL-2 synthesisVascular endothelial cellsQuantity of antigenHuman endothelial cellsAllogeneic responseMitogen phytohemagglutininMononuclear cellsIL-2Presence of EC
1988
REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW
Bierer B, Emerson S, Antin J, Maziarz R, Rappeport J, Smith B, Burakoff A. REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW. Transplantation 1988, 46: 835-839. PMID: 3061078, DOI: 10.1097/00007890-198812000-00009.Peer-Reviewed Original ResearchConceptsGraft rejectionHuman allogeneic bone marrow transplantationT cell-depleted marrowAllogeneic bone marrow transplantationClass I major histocompatibility complex antigensMajor histocompatibility complex antigensLymphocyte function-associated antigen-1Bone marrow transplantationFunction-associated antigen-1Cytotoxic T lymphocytesAnti-CD3 mAbHistocompatibility complex antigensBone marrow progenitor cellsMHC class IMarrow progenitor cellsNumber of mAbsBMT patientsCTL activityEffector cellsMarrow transplantationRecipient originT cellsT lymphocytesComplex antigensBone marrowPhenotypic and functional characterization of human cytolytic T cells lacking expression of CD5.
Bierer BE, Nishimura Y, Burakoff SJ, Smith BR. Phenotypic and functional characterization of human cytolytic T cells lacking expression of CD5. Journal Of Clinical Investigation 1988, 81: 1390-1397. PMID: 2452832, PMCID: PMC442569, DOI: 10.1172/jci113468.Peer-Reviewed Original ResearchConceptsAnti-CD3 mAbNormal cytolytic activityCytolytic activityHuman cytolytic T cellsNormal individualsLymphocyte function-associated antigen-3Blood mononuclear cellsImmunofluorescence flow cytometryCytolytic T cellsExpression of CD5T lymphocyte clonesT cell activationSurface CD3Appropriate target cellsMononuclear cellsNormal CD5CD5 antigenT cellsIntracellular calciumLymphocyte clonesCD5Cell activationCell membrane glycoproteinAntigen 3Lymphoid phenotype
1987
CTL adhesion and antigen recognition are discrete steps in the human CTL-target cell interaction.
Mentzer SJ, Smith BR, Barbosa JA, Crimmins MA, Herrmann SH, Burakoff SJ. CTL adhesion and antigen recognition are discrete steps in the human CTL-target cell interaction. The Journal Of Immunology 1987, 138: 1325-30. PMID: 3543126, DOI: 10.4049/jimmunol.138.5.1325.Peer-Reviewed Original ResearchConceptsHLA-A2CTL clonesHLA-B7Target cellsAntigen recognitionHuman CTL clonesTarget cell lysisCalcium-sensitive dye indo-1Cytolytic T lymphocytesCTL-target interactionDye indo-1CTL-target cell interactionAntigen-specific receptorsT cell receptorCell surface moleculesCTL activationT lymphocytesHuman CTLIndo-1LFA-1Free calciumCell receptorFlow cytometrySurface moleculesCell interactions
1985
Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity.
Smith BR, Rosenthal DS, Ault KA. Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Experimental Hematology 1985, 13: 189-93. PMID: 3884356.Peer-Reviewed Original ResearchConceptsHairy cell leukemiaNK cellsNatural killerFluorescence-activated cell sorterNK activityNK functionCell leukemiaFunctional deficiencyNormal numbersPhenotypic NK cellsMajority of patientsStandard 51Cr releaseSevere functional deficiencyDefective functional activityK562 targetsNK populationPatientsSurface markersK562 cell lineFunctional activityCell populationsCell sorterCell linesLeukemiaIdentifiable cells